This study combined UPLC-Q-TOF-MS/MS technology with network pharmacology to explore the anti-breast cancer mechanism of Poria cocos,and verified by cellular experiments for preliminary.There were 37 active components obtained from UPLC-Q-TOF-MS/MS data,then obtained 301 target components from drug database.A total of 725 differential genes were screened by breast cancer gene expression microarray through the GEO databases.After taking the intersection,30 potential targets of P. cocos in the treatment of breast cancer were obtained.PPI analysis showed that P. cocos mainly acted on PPARG,PPARA and other targets of anti-breast cancer.KEGG enrichment analysis showed that it was mainly related to PPAR signaling pathway.Molecular docking showed that the core components docked with the core targets stably,and the carboxyl,hydroxyl and ester groups on the corresponding carbon chains of the core components were the main functional groups for the binding targets.The results of the cell validation experiments showed that the P. cocos extract group could significantly inhibit the proliferation and migration of breast cancer cells,and obviously enhanced the fluorescence intensity of PPARG protein,which mainly distributed in the nucleus.In conclusion,this paper presents a preliminary study on the multi-target and multi-pathway therapeutic effect of P. cocos on breast cancer,the mechanism of which may be related to the regulation of PPARG and other targets,the inhibition of tumor cell proliferation and migration,and the influence of tumor cell metabolism.